NASDAQ:LNTH - Lantheus Stock Price, Forecast & News

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Lantheus Holdings Inc (NASDAQ:LNTH) released its quarterly earnings results on Thursday, October, 31st. The medical equipment provider reported $0.28 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.21 by $0.07. The medical equipment provider had revenue of $85.80 million for the quarter, compared to analyst estimates of $83.82 million. Lantheus had a net margin of 10.02% and a return on equity of 46.58%. The firm's revenue was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.24 earnings per share. View Lantheus' Earnings History.

Lantheus is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Lantheus.

Lantheus updated its fourth quarter earnings guidance on Thursday, October, 31st. The company provided earnings per share (EPS) guidance of $0.27-$0.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.34. The company issued revenue guidance of $89-$91 million, compared to the consensus revenue estimate of $92.84 million.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lantheus.

Media headlines about LNTH stock have trended positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Lantheus earned a daily sentiment score of 3.0 on InfoTrie's scale. They also assigned news coverage about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Lantheus.

Lantheus saw a increase in short interest in December. As of December 31st, there was short interest totalling 1,400,000 shares, an increase of 14.8% from the December 15th total of 1,220,000 shares. Based on an average trading volume of 370,000 shares, the days-to-cover ratio is presently 3.8 days. Approximately 3.7% of the shares of the stock are sold short. View Lantheus' Current Options Chain.

Some companies that are related to Lantheus include Myriad Genetics (MYGN), Heska (HSKA), Intellia Therapeutics (NTLA), Quotient (QTNT), Oxford Immunotec Global (OXFD), Meridian Bioscience (VIVO), Nymox Pharmaceutical (NYMX), Vermillion (VRML), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Arca Biopharma (ABIO), GeneNews (GNWSF) and Achieve Life Sciences (ACHV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include Mobileye (MBBYF), Energy Transfer LP Unit (ET), CBL & Associates Properties (CBL), Gerdau (GGB), NovaBay Pharmaceuticals (NBY), Akorn (AKRX), Cypress Semiconductor (CY), Exelixis (EXEL), Paratek Pharmaceuticals (PRTK) and AT&T (T).

(LNTH) raised $75 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

Lantheus' stock is owned by many different of institutional and retail investors. Top institutional investors include Tealwood Asset Management Inc. (0.19%), Bowling Portfolio Management LLC (0.07%), IFP Advisors Inc (0.04%), Louisiana State Employees Retirement System (0.03%) and FNY Investment Advisers LLC (0.01%). Company insiders that own Lantheus stock include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Robert J Jr Marshall, Sam R Leno, Timothy G Healey and Tudor Brown. View Institutional Ownership Trends for Lantheus.

LNTH stock was sold by a variety of institutional investors in the last quarter, including Bowling Portfolio Management LLC, IFP Advisors Inc, Tealwood Asset Management Inc. and Louisiana State Employees Retirement System. Company insiders that have sold Lantheus company stock in the last year include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, Mary Anne Heino, Michael P Duffy, Robert J Jr Marshall, Sam R Leno and Tudor Brown. View Insider Buying and Selling for Lantheus.

LNTH stock was bought by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. View Insider Buying and Selling for Lantheus.

Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LNTH stock can currently be purchased for approximately $18.76.

Lantheus has a market capitalization of $736.33 million and generates $343.37 million in revenue each year. The medical equipment provider earns $40.51 million in net income (profit) each year or $0.94 on an earnings per share basis. Lantheus employs 488 workers across the globe.View Additional Information About Lantheus.

The official website for Lantheus is http://www.lantheus.com/.

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]